Blog
RSS FeedPosted by Michael Wonder on 19 Aug 2016
Post-market review of biological disease modifying anti-rheumatic drugs to treat severe chronic plaque psoriasis and of pulmonary arterial hypertension medicines
19 August 2016 - The public consultation process on the draft terms of reference for the two post-market reviews has closed. ...
Posted by Michael Wonder on 19 Aug 2016
NICE issues draft guidance on the first-line use of sorafenib tosylate (Nexavar) in advanced/metastatic hepatocellular carcinoma
19 August 2016 - The merits of Nexavar in liver cancer have been reviewed by NICE under the CDF rapid reconsideration ...
Posted by Michael Wonder on 19 Aug 2016
HIV prevention drug Truvada won't be subsidised in Australia anytime soon
19 August 2016 - An expensive combination product that prevents people from getting HIV won't be funded by taxpayers in Australia ...
Posted by Michael Wonder on 18 Aug 2016
Subsidised access to new melanoma drugs: in need of further innovation?
19 August 2016 - New Zealand is now the melanoma capital of the world but is behind the rest of ...
Posted by Michael Wonder on 18 Aug 2016
Cancer drug appraisal needs to be reviewed
18 August 2016 - ABPI Executive pens letter to The Guardian. ...
Posted by Michael Wonder on 18 Aug 2016
NICE recommends crizotinib, first pill for lung cancer
18 August 2016 - New draft guidance from NICE means hundreds of people will now have access to crizotinib, a twice-a-day ...
Posted by Michael Wonder on 18 Aug 2016
PHARMAC calls on Tauranga for advice
18 August 2016 - PHARMAC is asking Tauranga people to help it make some changes to how it should best distribute ...
Posted by Michael Wonder on 18 Aug 2016
PHARMAC seeking community views on changes to funding application process
18 August 2016 - PHARMAC’s decisions affect nearly all New Zealanders, and the Government pharmaceutical funding agency is asking people to ...
Posted by Michael Wonder on 17 Aug 2016
Promise and plausibility: health technology adoption decisions with limited evidence
18 August 2016 - The adoption of new medical devices and diagnostics is often hampered by lack of published evidence which ...
Posted by Michael Wonder on 17 Aug 2016
Reform PHARMAC or people will die, melanoma survivor tells MPs
17 August 2016 - Leisa Renwick planned to spend Mother's Day last year with her family but ended up in Tauranga ...
Posted by Michael Wonder on 17 Aug 2016
UK patient groups urge government to negotiate drug prices
16 August 2016 - Arguing that cancer patients in the United Kingdom are missing out on new treatments, two leading charities ...
Posted by Michael Wonder on 17 Aug 2016
Proposed new drug guidelines for the PBS put cost-cutting before patients
17 August 2016 - The sustained accessibility of Australians to world-class medicines will be in question if proposed drug review guidelines ...
Posted by Michael Wonder on 17 Aug 2016
German body calls for pause in European plan for fast track drug approval
16 August 2016 - Plans by the European Medicines Agency to expand its fast track approach to approving new drugs have ...
Posted by Michael Wonder on 16 Aug 2016
German agency criticizes European program for speeding some drug approvals
15 August 2016 - in pointed remarks, Germany’s cost-effectiveness watchdog has criticized an effort by European regulators to accelerate approval ...
Posted by Michael Wonder on 15 Aug 2016
ABPI responds to the International Comparisons of Health Technology Assessment report and claims that patients are being denied life-prolonging treatments
15 August 2016 - The Association of the British Pharmaceuticals Industry has responded to the International Comparisons of Health Technology Assessment ...